公司资料
TScan Therapeutics, Inc. 股价、新闻与催化剂
- 股票代码:
- TCRX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.33 USD (+6.00%)
收盘价
最后更新: 2026年9月21日
64M USD
市值
股价为何变动
截至 2026年9月21日，TCRX 上涨 6.00%，收于 $0.3306。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
TScan Therapeutics is a cell-therapy company focused on T-cell receptor therapies for cancer. Its platform aims to create engineered T cells that can recognize tumor-specific targets.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, TScan sits in advanced cell therapy.
商业模式特征
The company depends on clinical validation, manufacturing execution, and the ability to develop a differentiated TCR platform.
生物医药行业定位
TScan is a high-catalyst cell-therapy name whose stock is highly sensitive to translational progress.
未来催化剂
- TScan’s catalysts are TCR-engineered cell therapy data and any update that shows the platform can handle solid tumors as well as hematologic disease. The stock will move if the clinical story keeps improving.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。